What did @sipgalbee actually say?
Honestly, not much, at least not verbally. The transcript is almost entirely song lyrics, "So now I say goodbye to the old me," layered over what appears to be a before-and-after weight loss comparison video tied to a year of Wegovy use for PCOS-related weight management. The real claim here is visual and emotional, not spoken: that semaglutide produced meaningful, visible body composition change over roughly 12 months. The hashtags do the heavy lifting, pointing viewers toward a semaglutide weight loss journey framed around PCOS.
This kind of video is extremely common on TikTok and it is worth separating the emotional resonance from medical specificity. There is nothing wrong with celebrating a health win. But 660,000 viewers are drawing clinical conclusions from a song snippet and a side-by-side photo, and that gap matters.
Does the science back this up?
Yes, to a real degree. The data on semaglutide for weight loss is among the strongest we have for any pharmacological intervention in obesity medicine. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that adults on 2.4mg subcutaneous semaglutide lost an average of 14.9% of body weight over 68 weeks compared to 2.4% in the placebo group. That is not a rounding error.
For PCOS specifically, the evidence is more limited but encouraging. A 2023 review in Frontiers in Endocrinology noted that GLP-1 receptor agonists appear to reduce androgen levels, improve insulin sensitivity, and support menstrual regularity in women with PCOS, though most studies are small and short-term. A year of consistent use aligning with visible transformation is biologically plausible and consistent with trial timelines. So the implicit claim here, that Wegovy works over 12 months for someone with PCOS, is not wrong.
What did they get wrong (or right)?
They did not get anything factually wrong, because they did not make a factual claim. That is actually the more interesting problem. The video implies a straightforward, broadly replicable result without acknowledging the variables that shape individual outcomes: starting dose, titration schedule, dietary changes, exercise habits, whether insurance covered it, side effect management, or what happened to weight when (and if) the drug was stopped.
The STEP 4 trial (Rubino et al., 2021, JAMA) showed that participants who discontinued semaglutide regained two-thirds of their lost weight within a year. That context is absent from the celebration, and viewers deserve to know it. Semaglutide is effective, but it is not a finite fix. Framing it as "goodbye to the old me" may inadvertently set expectations that the change is permanent without continued use or lifestyle infrastructure.
Credit where it is due: tagging PCOS explicitly is valuable. It signals to other women with the condition that this drug is being used for that indication, which can prompt real conversations with actual clinicians.
What should you actually know?
If you have PCOS and are considering semaglutide, there are a few things worth understanding before your first appointment. First, Wegovy (semaglutide 2.4mg) is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity. PCOS is generally considered a qualifying comorbidity in clinical practice, though coverage decisions vary by insurer.
Second, results vary significantly. The 15% average weight loss in STEP 1 is an average, meaning a meaningful portion of participants lost considerably less. Individual response depends on genetics, adherence, and metabolic factors.
Third, compounded semaglutide is not the same as Wegovy. Formulation, dosing, and quality controls differ. If a provider or pharmacy is steering you toward a compounded version, ask specific questions about sourcing and FDA status.
Finally, the drug works best as part of a broader approach. Clinical guidelines from the American Gastroenterological Association (Khanna et al., 2023) recommend GLP-1 agonists alongside behavioral interventions, not as standalone solutions.
The bottom line
This video is a personal celebration, not a medical endorsement, and it should be read that way. The science behind semaglutide for weight loss and PCOS is real and reasonably robust. But a 15-second emotional clip cannot carry the nuance that 660,000 viewers actually need. If this video made you curious about Wegovy, that curiosity is worth pursuing with a licensed clinician, not a TikTok comment section.